Goat gonad tissue

animal tissue

provenance:animal tissue

first introduced:1917

regulatory status:withdrawn

context:Brinkley began implanting fresh goat gonad tissue into human recipients at Milford, Kansas in 1917 (Smith 2022). The material was placed surgically and marketed as a glandular stimulus for sexual function and rejuvenation. The choice of goat tissue rested on promotional reasoning about animal virility rather than on any endocrinological evidence of cross-species compatibility.

MECHANISM CLAIMED

Implanted goat gonad tissue would take root in the human recipient and supply an ongoing glandular stimulus that restored sexual function and fertility and reversed the effects of aging.

MECHANISM ACTUAL

Goat gonad tissue implanted in a human is recognized as foreign and rejected by the recipient's immune system within days to weeks. No integration and no sustained endocrine contribution is biologically possible, and no goat-derived hormone reaches the recipient's circulation from the implant. Reported benefits are consistent with placebo response, postoperative attention, and patient self-report; the operation also carried the ordinary surgical risks of infection and operative injury.

INTERVENTIONS USING IT

Brinkley goat-gland transplantation (goat-to-human gonad implant)

NOTES

Goat gonad tissue was the active material in Brinkley’s operation from 1917. It is the American, goat-sourced member of the animal-gonad-tissue lineage that runs through Brown-Sequard’s testicular extract (1889) and Voronoff’s chimpanzee xenograft (1920): the same logic of transferring gonad tissue from an animal into a paying human recipient to restore vigor, with the donor species chosen for its folk association with virility rather than for any demonstrated biological compatibility. The use was abandoned as immunology and endocrinology made clear that the implant could neither integrate nor deliver hormone, and it survives only as a documented episode in the history of medical fraud.